CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
树突状细胞来源外泌体在肿瘤免疫治疗中的最新进展
英文原题：Recent progress of dendritic cell-derived exosomes in tumor immunotherapy.
查看英文原题
Recent progress of dendritic cell-derived exosomes in tumor immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管包括手术和化疗在内的传统肿瘤疗法取得了进展，但由于治疗耐药性和肿瘤微环境的复杂性，有效的癌症管理仍然具有挑战性。基于树突状细胞（DC）的疫苗虽然是肿瘤免疫治疗的一个里程碑，但面临临床局限性，如活力差和抗原呈递能力有限。重要的是，树突状细胞来源的外泌体（DEXs）已成为一种潜在的替代方案。与DC疫苗相比，DEXs具有优异的体内生物相容性和生物安全性，表现出更高的免疫原性，展现出更强的免疫抑制抵抗能力，并且生产成本更低。在机制上，DEXs通过双重递送免疫刺激货物和肿瘤相关抗原克服免疫抑制障碍，从而实现更优越的抗肿瘤效果。本综述审视了DEXs在肿瘤免疫治疗中的最新研究进展，特别强调其在免疫激活、肿瘤微环境调控、作为药物递送载体以及疫苗开发中的作用。这些进展将有助于加深对肿瘤免疫治疗的理解并促进临床转化。
展开英文摘要原文
Despite advancements in conventional tumor therapies including surgery and chemotherapy, effective cancer management remains challenging due to treatment resistance and tumor microenvironment complexity. Dendritic cell (DC)-based vaccines, while representing a milestone in tumor immunotherapy, face clinical limitations such as poor viability and limited antigen presentation capacity.
Importantly, dendritic cell-derived exosomes (DEXs) have emerged as a potential alternative. In contrast to DC vaccines, DEXs possess excellent in vivo biocompatibility and biosafety, demonstrate higher immunogenicity, exhibit stronger immunosuppressive resistance, and require lower production costs.
Mechanistically, DEXs overcome immunosuppressive obstacles through dual delivery of immunostimulatory cargo and tumor-associated antigens, thereby achieving superior anti-tumor effects. This review examines recent research progress regarding DEXs in tumor immunotherapy, with particular emphasis on their roles in immune activation, the regulation of the tumor microenvironment, serving as drug delivery vehicles, and vaccine development. These advancements will help deepen the understanding of tumor immunotherapy and promote clinical translation.
论文信息
- 作者
- Wang B、Hu Y、Zhou Y、Han Q、Huang Y、Dong Y、Zhang Y、Guo Z
- 第一作者单位
- Medical College, Henan University of Chinese Medicine, No. 156, Jinshui East Road, Zhengzhou, 450046, China.China
- 通讯作者单位
- Medical College, Henan University of Chinese Medicine, No. 156, Jinshui East Road, Zhengzhou, 450046, China. fsy@hactcm.edu.cn.China
- 文献类型
- 综述
- 期刊
- Investigational new drugs2026 Apr
- 原文标识
- PubMed 41954838 · DOI 10.1007/s10637-026-01604-4